{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:23:05Z","timestamp":1761747785967,"version":"build-2065373602"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100031006","name":"Bowen University","doi-asserted-by":"publisher","award":["BRE\/2021\/014","BRE\/2021\/014","BRE\/2021\/014","BRE\/2021\/014","BRE\/2021\/014"],"award-info":[{"award-number":["BRE\/2021\/014","BRE\/2021\/014","BRE\/2021\/014","BRE\/2021\/014","BRE\/2021\/014"]}],"id":[{"id":"10.13039\/100031006","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In many countries, the preliminary stage of the COVID-19 pandemic has reached its climax and serological studies are extremely important in managing public health responses to the COVID-19 pandemic caused by SARS-CoV-2. The Nucleocapsid protein, a highly immunogenic protein, found only in infected individuals is important in SARS-CoV-2 infection. This study was therefore designed to determine the seroprevalence of SARS-CoV-2 IgM and IgG antibodies to nucleocapsid proteins in Iwo, Nigeria, thereby providing information on the spread of the infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Five millilitres of blood were collected from 360 individuals visiting four selected hospitals in Iwo, Nigeria. Socio-demographic and clinical data of the participants were obtained through a structured questionnaire. SARS-CoV-2 IgM and IgG antibodies against the nucleocapsid protein were detected from plasma samples using commercially available Enzyme-linked Immunoassay kits (Monobind Inc, USA) according to the manufacturer\u2019s instructions. Statistical analyses were performed using SPSS software version 21 at\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.05 for statistical significance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Out of the tested samples, 37 and 165 were positive for IgM and IgG antibodies giving a prevalence of 10.3% [95% CI: 7.5% \u2212 13.6%] and 45.8% [95% CI: 40.8% \u2212 50.8%], respectively. In total, 184 samples tested positive for SARS-CoV-2 antibodies giving an overall prevalence of 51.1% [95% CI: 45.8% \u2212 56.1%]. Infection was associated with age; older population (35\u201390 years), fever, cough and muscle pain (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). SARS-CoV-2 IgM and IgG antibodies were detected among 11.8% and 42.6% of COVID-19 vaccine recipients, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High seroprevalence of SARS-CoV-2 antibodies to nucleocapsid proteins were detected among the study population. In particular, is detecting IgM antibodies among those who have received COVID-19 vaccines. This reveals a high level of recent and past exposure to SARS-CoV-2 virus infection and continuous spread within the community.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11850-1","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:44:58Z","timestamp":1761741898000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Seroprevalence of Immunoglobulin M and G antibodies to severe acute respiratory syndrome coronavirus 2 infection in Iwo, Nigeria"],"prefix":"10.1186","volume":"25","author":[{"given":"Yewande Tolulope","family":"Nejo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oladipo Olarinre","family":"Oladosu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew Idowu","family":"Olatubi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abimbola Adetokunboh","family":"Owoseni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel Olatunde","family":"Dahunsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"issue":"10229","key":"11850_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, china: a retrospective cohort study. Lancet. 2020;395(10229):1054\u201362.","journal-title":"Lancet"},{"key":"11850_CR2","unstructured":"World Health Organization. \u2018Coronavirus disease (COVID-19) pandemic. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019 (2024). Accessed 30 July 2024."},{"issue":"3","key":"11850_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181\u201392. https:\/\/doi.org\/10.1038\/s41579-018-0118-9.","journal-title":"Nat Rev Microbiol"},{"issue":"8","key":"11850_CR4","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14(8):523\u201334. https:\/\/doi.org\/10.1038\/nrmicro.2016.81.","journal-title":"Nat Rev Microbiol"},{"key":"11850_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/bs.aivir.2018.01.001","volume":"100","author":"VM Corman","year":"2018","unstructured":"Corman VM, Muth D, Niemeyer D, Drosten C. Hosts and sources of endemic human coronaviruses. Adv Virus Res. 2018;100:163\u201388. https:\/\/doi.org\/10.1016\/bs.aivir.2018.01.001.","journal-title":"Adv Virus Res"},{"issue":"10224","key":"11850_CR6","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(20)30251-8.","journal-title":"Lancet"},{"issue":"3","key":"11850_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s11427-020-1783-9","volume":"64","author":"N Zhang","year":"2021","unstructured":"Zhang N, Gong Y, Meng F, Shi Y, Wang J, Mao P, et al. Comparative study on virus shedding patterns in nasopharyngeal and faecal specimens of COVID-19 patients. Sci China Life Sci. 2021;64(3):486\u20138. https:\/\/doi.org\/10.1007\/s11427-020-1783-9.","journal-title":"Sci China Life Sci"},{"key":"11850_CR8","unstructured":"Nigeria Centre for Disease Control. COVID-19 Outbreak in Nigeria Situation Report. S\/N 001. https:\/\/covid19.ncdc.gov.ng\/ (2020). Accessed 29 Nov 2020."},{"key":"11850_CR9","unstructured":"WorldoMeters. 2023. https:\/\/www.worldometers.info\/world-population\/nigeria-population\/. Accessed 23 Oct 2023."},{"key":"11850_CR10","unstructured":"WorldoMeters. Nigeria COVID. - Coronavirus Statistics. 2024. https:\/\/www.worldometers.info\/coronavirus\/country\/nigeria\/. Accessed 30 Jul 2024."},{"key":"11850_CR11","unstructured":"Nigeria Centre for Disease Control. COVID-19 Outbreak in Nigeria Situation Report. https:\/\/covid19.ncdc.gov.ng\/ (2023). Accessed 23 Oct 2023."},{"key":"11850_CR12","unstructured":"Nigeria Centre for Disease Control. An update of COVID-19 outbreak in Nigeria_280720_31.pdf: COVID-19 Situation Reports 151. https:\/\/ncdc.gov.ng\/diseases\/sitrep (2020). Accessed 28 Jul 2020."},{"issue":"6","key":"11850_CR13","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7326\/M20-2854","volume":"173","author":"MP Cheng","year":"2020","unstructured":"Cheng MP, Yansouni CP, Basta NE, Desjardins M, Kanjilal S, Paquette K, et al. Serodiagnostics for severe acute respiratory Syndrome-Related coronavirus 2: A narrative review. Ann Intern Med. 2020;173(6):450\u201360. https:\/\/doi.org\/10.7326\/M20-2854.","journal-title":"Ann Intern Med"},{"key":"11850_CR14","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12985-023-01968-6","volume":"20","author":"W Wu","year":"2023","unstructured":"Wu W, Cheng Y, Zhou H, Sun C, Zhang S. The SARS\u2013CoV\u20132 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics. Virol J. 2023;20:6. https:\/\/doi.org\/10.1186\/s12985-023-01968-6.","journal-title":"Virol J"},{"key":"11850_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.bbrc.2020.09.131","volume":"538","author":"L Zinzula","year":"2021","unstructured":"Zinzula L, Basquin J, Bohn S, Beck F, Klumpe S, Pfeifer G, et al. High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2. Biochem Biophys Res Commun. 2021;538:54\u201362.","journal-title":"Biochem Biophys Res Commun"},{"key":"11850_CR16","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.antiviral.2013.12.009","volume":"103","author":"CK Chang","year":"2014","unstructured":"Chang CK, Hou MH, Chang CF, Hsiao CD, Huang TH. The SARS coronavirus nucleocapsid protein\u2013forms and functions. Antiviral Res. 2014;103:39\u201350.","journal-title":"Antiviral Res"},{"key":"11850_CR17","doi-asserted-by":"publisher","unstructured":"Burbelo PD, Riedo FX, Morishima C, Rawlings S, Smith D, Das S et al. Detection of nucleocapsid antibody to SARS-CoV-2 is more sensitive than antibody to spike protein in COVID-19 patients. medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020. 04. 20. 20071 423.","DOI":"10.1101\/2020"},{"issue":"6504","key":"11850_CR18","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1126\/science.abd3902","volume":"369","author":"M Mbow","year":"2020","unstructured":"Mbow M, Lell B, Jochems SP, Cisse B, Mboup S, Dewals BG, et al. COVID-19 in africa: dampening the storm? Science. 2020;369(6504):624\u20136. https:\/\/doi.org\/10.1126\/science.abd3902.","journal-title":"Science"},{"key":"11850_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/s41562-020-0870-5","volume":"4","author":"C Payne","year":"2020","unstructured":"Payne C. COVID-19 in Africa. Nat Hum Behav. 2020;4:436\u20137. https:\/\/doi.org\/10.1038\/s41562-020-0870-5.","journal-title":"Nat Hum Behav"},{"issue":"5","key":"11850_CR20","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1093\/ije\/dyac141","volume":"51","author":"GD Chechet","year":"2022","unstructured":"Chechet GD, Kwaga JKP, Yahaya J, Noyes H, MacLeod A, Adamson WE. SARS-CoV-2 Seroprevalence at urban and rural sites in Kaduna State, Nigeria, during October\/November 2021, immediately prior to detection of the Omicron variant. Int J Epidemiol. 2022;51(5):1361\u201370. https:\/\/doi.org\/10.1093\/ije\/dyac141.","journal-title":"Int J Epidemiol"},{"key":"11850_CR21","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ijid.2021.07.040","volume":"110","author":"OV Okpala","year":"2021","unstructured":"Okpala OV, Dim CC, Ugwu CI, Onyemaechi S, Uchebo O, Chukwulobelu U, et al. Population Seroprevalence of SARS-CoV-2 antibodies in Anambra State, South-East, Nigeria. Int J Infect Dis. 2021;110:171\u20138.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"11850_CR22","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4269\/ajtmh.20-1235","volume":"104","author":"O Olayanju","year":"2021","unstructured":"Olayanju O, Bamidele O, Edem F, Eseile B, Amoo A, Nwaokenye J, et al. SARS-CoV-2 seropositivity in asymptomatic frontline health workers in Ibadan, Nigeria. Am J Trop Med Hyg. 2021;104(1):91\u20134. https:\/\/doi.org\/10.4269\/ajtmh.20-1235.","journal-title":"Am J Trop Med Hyg"},{"issue":"10","key":"11850_CR23","doi-asserted-by":"publisher","first-page":"e2236053","DOI":"10.1001\/jamanetworkopen.2022.36053","volume":"5","author":"OM Kolawole","year":"2022","unstructured":"Kolawole OM, Tomori O, Agbonlahor D, Ekanem E, Bakare R, Abdulsalam N, et al. SARS CoV-2 Seroprevalence in selected States of high and low disease burden in Nigeria. JAMA Netw Open. 2022;5(10):e2236053. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.36053.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"11850_CR24","doi-asserted-by":"publisher","first-page":"e0280276","DOI":"10.1371\/journal.pone.0280276","volume":"18","author":"AA Onifade","year":"2023","unstructured":"Onifade AA, Fowotade A, Rahamon SK, Edem VF, Yaqub SA, Akande OK, et al. Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine na\u00efve adult Nigerians. PLoS ONE. 2023;18(1):e0280276.","journal-title":"PLoS ONE"},{"key":"11850_CR25","doi-asserted-by":"publisher","first-page":"215013272094269","DOI":"10.1177\/2150132720942695","volume":"11","author":"M Takita","year":"2020","unstructured":"Takita M, Matsumura T, Yamamoto K, Yamashita E, Hosoda K, Hamaki T, et al. Geographical profiles of COVID-19 outbreak in tokyo: an analysis of the primary care clinic\u2013based point-of-care antibody testing. J Prim Care amp; Community Health. 2020;11:2150132720942695.","journal-title":"J Prim Care amp; Community Health"},{"issue":"1","key":"11850_CR26","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41467-021-21237-w","volume":"12","author":"H Ward","year":"2021","unstructured":"Ward H, Atchison C, Whitaker M, Ainslie KEC, Elliott J, Okell L, et al. SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic. Nat Commun. 2021;12(1):905. https:\/\/doi.org\/10.1038\/s41467-021-21237-w.","journal-title":"Nat Commun"},{"issue":"10","key":"11850_CR27","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S1473-3099(20)30471-0","volume":"20","author":"QL Jing","year":"2020","unstructured":"Jing QL, Liu MJ, Zhang ZB, Fang LQ, Yuan J, Zhang AR, et al. Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, china: a retrospective cohort study. Lancet Infect Dis. 2020;20(10):1141\u201350. https:\/\/doi.org\/10.1016\/S1473-3099(20)30471-0.","journal-title":"Lancet Infect Dis"},{"key":"11850_CR28","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1001\/jama.2020.8279","volume":"323","author":"N Sood","year":"2020","unstructured":"Sood N, Simon P, Ebner P, Eichner D, Reynolds J, Bendavid E, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10\u201311, 2020. JAMA. 2020;323:2425\u20137. https:\/\/doi.org\/10.1001\/jama.2020.8279.","journal-title":"JAMA"},{"key":"11850_CR29","doi-asserted-by":"publisher","first-page":"41317","DOI":"10.11604\/pamj.2022.41.317.34307","volume":"20","author":"R Utulu","year":"2022","unstructured":"Utulu R, Ajayi IO, Bello S, Balogun MS, Madubueze UC, Adeyemi IT, et al. Risk factors for COVID-19 infection and disease severity in nigeria: a case-control study. Pan Afr Med J. 2022;20:41317. https:\/\/doi.org\/10.11604\/pamj.2022.41.317.34307.","journal-title":"Pan Afr Med J"},{"issue":"8","key":"11850_CR30","doi-asserted-by":"publisher","first-page":"e10114","DOI":"10.7759\/cureus.10114","volume":"12","author":"M Kelada","year":"2020","unstructured":"Kelada M, Anto A, Dave K, Saleh SN. The role of sex in the risk of mortality from COVID-19 amongst adult patients: A systematic review. Cureus. 2020;12(8):e10114. https:\/\/doi.org\/10.7759\/cureus.10114.","journal-title":"Cureus"},{"issue":"3","key":"11850_CR31","doi-asserted-by":"publisher","first-page":"e024746","DOI":"10.1371\/journal.pone.0247461","volume":"16","author":"A Booth","year":"2021","unstructured":"Booth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: a global systematic review and meta-analysis. PLoS ONE. 2021;16(3):e024746.","journal-title":"PLoS ONE"},{"issue":"4","key":"11850_CR32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1515\/dx-2020-0054","volume":"7","author":"J Vikse","year":"2020","unstructured":"Vikse J, Lippi G, Henry BM. Do sex-specific Immunobiological factors and differences in angiotensin converting enzyme 2 (ACE2) expression explain increased severity and mortality of COVID-19 in males? Diagnosis (Berl). 2020;7(4):385\u20136. https:\/\/doi.org\/10.1515\/dx-2020-0054.","journal-title":"Diagnosis (Berl)"},{"issue":"9","key":"11850_CR33","doi-asserted-by":"publisher","first-page":"e1003346","DOI":"10.1371\/journal.pmed.1003346","volume":"17","author":"D Buitrago-Garcia","year":"2020","unstructured":"Buitrago-Garcia D, Egli-Gany D, Counotte MJ, Hossmann S, Imeri H, Ipekci AM, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: a living systematic review and meta-analysis. PLoS Med. 2020;17(9):e1003346. https:\/\/doi.org\/10.1371\/journal.pmed.1003346.","journal-title":"PLoS Med"},{"issue":"10","key":"11850_CR34","doi-asserted-by":"publisher","first-page":"2000180","DOI":"10.2807\/1560-7917.ES.2020.25.10.2000180","volume":"25","author":"K Mizumoto","year":"2020","unstructured":"Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond Princess cruise ship, Yokohama, Japan, 2020. Euro Surveill. 2020;25(10):2000180. https:\/\/doi.org\/10.2807\/1560-7917.ES.2020.25.10.2000180.","journal-title":"Euro Surveill"},{"key":"11850_CR35","doi-asserted-by":"publisher","first-page":"03094","DOI":"10.7189\/jogh.11.03094","volume":"11","author":"AI Al-Mustapha","year":"2021","unstructured":"Al-Mustapha AI, Tijani AA, Oyewo M, Ibrahim A, Elelu N, Ogundijo OA, et al. Nigeria\u2019s race to zero COVID-19 cases: true disease burden or testing failure? J Glob Health. 2021;11:03094. https:\/\/doi.org\/10.7189\/jogh.11.03094.","journal-title":"J Glob Health"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11850-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11850-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11850-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:45:02Z","timestamp":1761741902000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-11850-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11850"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11850-1","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"21 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for the study was given by the Osun State Ministry of Health Research Ethics Committee in Nigeria with the reference number OSHREC\/PRS\/569T\/238. Written informed consent was received from all the participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1442"}}